ID: ALA2392254

Max Phase: Preclinical

Molecular Formula: C19H20N2O3

Molecular Weight: 324.38

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC(C)C(=O)Nc1cc(NC(=O)/C=C/c2ccccc2)ccc1O

Standard InChI:  InChI=1S/C19H20N2O3/c1-13(2)19(24)21-16-12-15(9-10-17(16)22)20-18(23)11-8-14-6-4-3-5-7-14/h3-13,22H,1-2H3,(H,20,23)(H,21,24)/b11-8+

Standard InChI Key:  NUPJUHSKXHMONH-DHZHZOJOSA-N

Associated Targets(non-human)

Neuraminidase 2284 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 324.38Molecular Weight (Monoisotopic): 324.1474AlogP: 3.64#Rotatable Bonds: 5
Polar Surface Area: 78.43Molecular Species: NEUTRALHBA: 3HBD: 3
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.72CX Basic pKa: CX LogP: 3.75CX LogD: 3.73
Aromatic Rings: 2Heavy Atoms: 24QED Weighted: 0.45Np Likeness Score: -0.79

References

1. Xie Y, Huang B, Yu K, Shi F, Liu T, Xu W..  (2013)  Caffeic acid derivatives: a new type of influenza neuraminidase inhibitors.,  23  (12): [PMID:23664211] [10.1016/j.bmcl.2013.04.033]

Source